Liquidia showcases PRINT vaccine technology at conference
PRINT technology involves particle engineering and enables Liquidia to accurately tailor a specific particle’s shape, size, hydrophobicity, charge and composition. These specifics impact the vaccine’s ability to provoke an immune response from the human body.
Liquidia has used its PRINT technology to create specialized particle systems that provoke an enhanced cellular and humoral immune response from the human body. This was accomplished through a variety of matrix materials with adjuvants and antigens.
At present, Liquidia is using PRINT technology for solutions to problems that are often raised in the vaccine-development industry. Company leaders said the ultimate goal is to make vaccines that are safe and effective, and that provide the widest range of protection for the world’s populations.
Dr. Michele Stone, executive director of vaccines at Liquidia Technologies, presented the information under the title “Utilizing PRINT Technology to Advance Vaccine Development.”